TW9
目录号 : KG10493
CAS No. : 2614417-90-0
纯度 : 98%
TW9 is a dual inhibitor of bromodomain 2 (BD2) in bromodomain-containing protein 4 (BRD4) and histone deacetylase 1 (HDAC1; IC50s = 0.074 and 0.29 µM, respectively). It is selective for BD2 over BD1 in BRD4 (IC50 = 0.72 µM) and for HDAC1 over HDAC2 (IC50 = 2.5 µM). TW9 (50 nM) induces apoptosis in, and inhibits proliferation of, MIA PaCa-2 pancreatic cancer cells. It induces cell cycle arrest at the G1 phase in HPAC pancreatic cancer cells when used at a concentration of 2 µM. TW9 acts synergistically with gemcitabine to reduce the viability of HPAC cells.
Other Forms of Rapamycin:
KKL Med 的所有产品和服务仅用于科学研究,不能被用于人体,兽医,我们也不向个人提供产品和服务。
KKL 顾客使用本产品发表的 0 篇科研文献
暂无科研文献
| 分子式 |
C32H28ClN7O2S
|
| 分子量 |
610.1
|
| CAS号 |
2614417-90-0
|
| 中文名称 |
NND-2242001
|
| 储存方式 |
| Powder |
-20°C |
3 years |
| |
4°C |
2 years |
| In solvent |
-80°C |
6 months |
| |
-20°C |
1 month |
|